Arakawa, Japan

Seiji Minota

This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2011-2016.

USPTO Granted Patents = 2 

% Patents Active = 50.0


Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 41(Granted Patents)


Location History:

  • Tokyo, JP (2011)
  • Arakawa, JP (2016)

Company Filing History:


Years Active: 2011-2016

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Seiji Minota: Innovator in Therapeutic Agents

Introduction

Seiji Minota is a notable inventor based in Arakawa, Japan. He has made significant contributions to the field of medicine, particularly in developing therapeutic agents for chronic arthritides diseases in children. With a total of 2 patents, his work is recognized for its potential impact on pediatric healthcare.

Latest Patents

Minota's latest patents focus on a therapeutic agent for chronic arthritides diseases related to childhood. This innovative agent comprises an interleukin-6 (IL-6) antagonist as an active ingredient. The therapeutic agent aims to address conditions such as Still's disease and other chronic arthritides diseases affecting children.

Career Highlights

Seiji Minota is associated with Chugai Seiyaku Kabushiki Kaisha, a prominent pharmaceutical company. His work at Chugai has allowed him to explore and develop groundbreaking treatments that can significantly improve the quality of life for children suffering from chronic arthritides diseases.

Collaborations

Minota has collaborated with esteemed colleagues, including Norihiro Nishimoto and Kazuyuki Yoshizaki. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to the development of effective therapeutic solutions.

Conclusion

Seiji Minota's contributions to the field of medicine through his patents and collaborations highlight his dedication to improving pediatric healthcare. His innovative work continues to pave the way for advancements in treating chronic arthritides diseases in children.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…